

Raquel Abalo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5614968/publications.pdf>

Version: 2024-02-01

81
papers

2,779
citations

201674
27
h-index

189892
50
g-index

82
all docs

82
docs citations

82
times ranked

3544
citing authors

#	ARTICLE	IF	CITATIONS
1	Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?. <i>Frontiers in Pharmacology</i> , 2018, 9, 245.	3.5	611
2	Antiproliferative and palliative activity of flavonoids in colorectal cancer. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112241.	5.6	151
3	Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments. <i>Frontiers in Pharmacology</i> , 2016, 7, 414.	3.5	150
4	Food, nutrients and nutraceuticals affecting the course of inflammatory bowel disease. <i>Pharmacological Reports</i> , 2016, 68, 816-826.	3.3	109
5	Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3067.	4.1	108
6	Radiological study of gastrointestinal motor activity after acute cisplatin in the rat. Temporal relationship with pica. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2008, 141, 54-65.	2.8	82
7	WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. <i>Life Sciences</i> , 2007, 81, 468-479.	4.3	67
8	Cisplatin-induced gastrointestinal dysmotility is aggravated after chronic administration in the rat. Comparison with pica. <i>Neurogastroenterology and Motility</i> , 2010, 22, 797-e225.	3.0	67
9	Enteric neuropathy evoked by repeated cisplatin in the rat. <i>Neurogastroenterology and Motility</i> , 2011, 23, 370-e163.	3.0	67
10	Gastrointestinal dysfunction and enteric neurotoxicity following treatment with anticancer chemotherapeutic agent 5-fluorouracil. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1861-1875.	3.0	65
11	Mechanisms of Chemotherapy-Induced Neurotoxicity. <i>Frontiers in Pharmacology</i> , 2022, 13, 750507.	3.5	64
12	The Gastrointestinal Pharmacology of Cannabinoids: Focus on Motility. <i>Pharmacology</i> , 2012, 90, 1-10.	2.2	55
13	Characterization of cannabinoid-induced relief of neuropathic pain in a rat model of cisplatin-induced neuropathy. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 105, 205-212.	2.9	53
14	Altered feeding behaviour induced by long-term cisplatin in rats. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2006, 126-127, 81-92.	2.8	48
15	Effects of Coffee and Its Components on the Gastrointestinal Tract and the Brain-Gut Axis. <i>Nutrients</i> , 2021, 13, 88.	4.1	48
16	Gene Expression of VIP Receptor in Rat Lymphocytes. <i>Biochemical and Biophysical Research Communications</i> , 1994, 203, 1599-1604.	2.1	46
17	Cannabinoid/agonist WIN 55,212-2 reduces cardiac ischaemia-reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS/eNOS. <i>Diabetes/Metabolism Research and Reviews</i> , 2011, 27, 331-340.	4.0	42
18	Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 102, 335-343.	2.9	40

#	ARTICLE	IF	CITATIONS
19	Cannabinoid pharmacology and therapy in gut disorders. <i>Biochemical Pharmacology</i> , 2018, 157, 134-147.	4.4	38
20	Ileal myenteric plexus in aged guinea-pigs: loss of structure and calretinin-immunoreactive neurones. <i>Neurogastroenterology and Motility</i> , 2005, 17, 123-132.	3.0	37
21	Selective lack of tolerance to delayed gastric emptying after daily administration of WIN 55,212-2 in the rat. <i>Neurogastroenterology and Motility</i> , 2009, 21, 1002.	3.0	36
22	Long-Acting Fentanyl Analogues: Synthesis and Pharmacology of N-(1-Phenylpyrazolyl)-N-(1-phenylalkyl-4-piperidyl)propanamides. <i>Bioorganic and Medicinal Chemistry</i> , 2002, 10, 817-827.	3.0	35
23	Oxaliplatin-induced enteric neuronal loss and intestinal dysfunction is prevented by co-treatment with BCP-15. <i>British Journal of Pharmacology</i> , 2018, 175, 656-677.	5.4	34
24	Cannabinoid-induced delayed gastric emptying is selectively increased upon intermittent administration in the rat: role of CB1 receptors. <i>Neurogastroenterology and Motility</i> , 2011, 23, 457.	3.0	32
25	Mast Cell Regulation and Irritable Bowel Syndrome: Effects of Food Components with Potential Nutraceutical Use. <i>Molecules</i> , 2020, 25, 4314.	3.8	32
26	An Assessment of the Bioactivity of Coffee Silverskin Melanoidins. <i>Foods</i> , 2019, 8, 68.	4.3	31
27	May cannabinoids prevent the development of chemotherapy-induced diarrhea and intestinal mucositis? Experimental study in the rat. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12952.	3.0	29
28	Characterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments. <i>Frontiers in Pharmacology</i> , 2017, 8, 196.	3.5	27
29	Cannabinoids may worsen gastric dysmotility induced by chronic cisplatin in the rat. <i>Neurogastroenterology and Motility</i> , 2013, 25, 373.	3.0	26
30	X-ray analysis of gastrointestinal motility in conscious mice. Effects of morphine and comparison with rats. <i>Neurogastroenterology and Motility</i> , 2016, 28, 74-84.	3.0	26
31	Inhibition of APE1/Ref-1 Redox Signaling Alleviates Intestinal Dysfunction and Damage to Myenteric Neurons in a Mouse Model of Spontaneous Chronic Colitis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 388-406.	1.9	26
32	Targeting Enteric Neurons and Plexitis for the Management of Inflammatory Bowel Disease. <i>Current Drug Targets</i> , 2020, 21, 1428-1439.	2.1	26
33	In vitro and non-invasive in vivo effects of the cannabinoid CB1 receptor agonist AM841 on gastrointestinal motor function in the rat. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1721-1735.	3.0	24
34	Peripherally acting opioid analgesics and peripherally-induced analgesia. <i>Behavioural Pharmacology</i> , 2020, 31, 136-158.	1.7	24
35	The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat. <i>Neurogastroenterology and Motility</i> , 2010, 22, 694-e206.	3.0	23
36	Age-related changes in the gastrointestinal tract: a functional and immunohistochemical study in guinea-pig ileum. <i>Life Sciences</i> , 2007, 80, 2436-2445.	4.3	22

#	ARTICLE	IF	CITATIONS
37	Alterations in the small intestinal wall and motor function after repeated cisplatin in rat. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13047.	3.0	21
38	Irinotecan-Induced Gastrointestinal Dysfunction Is Associated with Enteric Neuropathy, but Increased Numbers of Cholinergic Myenteric Neurons. <i>Frontiers in Physiology</i> , 2017, 8, 391.	2.8	21
39	Synthesis and opioid activity of new fentanyl analogs. <i>Life Sciences</i> , 2002, 71, 1023-1034.	4.3	20
40	Coffee and Caffeine Consumption for Human Health. <i>Nutrients</i> , 2021, 13, 2918.	4.1	19
41	Effects of chronic dietary exposure to monosodium glutamate on feeding behavior, adiposity, gastrointestinal motility, and cardiovascular function in healthy adult rats. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1559-1570.	3.0	18
42	Preclinical evaluation of the effects on the gastrointestinal tract of the antineoplastic drug vincristine repeatedly administered to rats. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13399.	3.0	17
43	Bioaccessibility, Metabolism, and Excretion of Lipids Composing Spent Coffee Grounds. <i>Nutrients</i> , 2019, 11, 1411.	4.1	16
44	Guanylate Cyclase C: A Current Hot Target, from Physiology to Pathology. <i>Current Medicinal Chemistry</i> , 2018, 25, 1879-1908.	2.4	16
45	X-ray analysis of the effect of the 5-HT ₃ receptor antagonist granisetron on gastrointestinal motility in rats repeatedly treated with the antitumoral drug cisplatin. <i>Experimental Brain Research</i> , 2014, 232, 2601-2612.	1.5	15
46	Involvement of Cannabinoid Signaling in Vincristine-Induced Gastrointestinal Dysmotility in the Rat. <i>Frontiers in Pharmacology</i> , 2017, 8, 37.	3.5	15
47	Evaluation of the effect of age on cannabinoid receptor functionality and expression in guinea-pig ileum longitudinal muscleâ€”myenteric plexus preparations. <i>Neuroscience Letters</i> , 2005, 383, 176-181.	2.1	14
48	Probiotics in digestive, emotional, and pain-related disorders. <i>Behavioural Pharmacology</i> , 2018, 29, 103-119.	1.7	14
49	Alterations of colonic sensitivity and gastric dysmotility after acute cisplatin and granisetron. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13499.	3.0	14
50	Painful neurotrophins and their role in visceral pain. <i>Behavioural Pharmacology</i> , 2018, 29, 120-139.	1.7	11
51	Radiographic doseâ€”dependency study of loperamide effects on gastrointestinal motor function in the rat. Temporal relationship with nauseaâ€”like behavior. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13621.	3.0	9
52	Nutraceuticals and Enteric Glial Cells. <i>Molecules</i> , 2021, 26, 3762.	3.8	9
53	Cannabinoid drugs against chemotherapy-induced adverse effects: focus on nausea/vomiting, peripheral neuropathy and chemofog in animal models. <i>Behavioural Pharmacology</i> , 2022, 33, 105-129.	1.7	9
54	Calcitonin reverts pertussis toxin blockade of the opioid analgesia in mice. <i>Neuroscience Letters</i> , 1999, 273, 175-178.	2.1	8

#	ARTICLE	IF	CITATIONS
55	Blockade by pertussis toxin of the opioid effect on guinea pig ileum. Contractility and electrophysiological neuronal recording. <i>Neuroscience Letters</i> , 2000, 291, 131-134.	2.1	7
56	Postnatal maturation of the gastrointestinal tract: A functional and immunohistochemical study in the guinea-pig ileum at weaning. <i>Neuroscience Letters</i> , 2009, 467, 105-110.	2.1	7
57	Changes in the diet composition of fatty acids and fiber affect the lower gastrointestinal motility but have no impact on cardiovascular parameters: In vivo and in vitro studies. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13651.	3.0	7
58	Cannabinoids and Effects on the Gastrointestinal Tract: A Focus on Motility. , 2017, , 947-957.		6
59	May a sigma μ 1 antagonist improve neuropathic signs induced by cisplatin and vincristine in rats?. <i>European Journal of Pain</i> , 2018, 23, 603-620.	2.8	6
60	Fluoroscopic Characterization of Colonic Dysmotility Associated to Opioid and Cannabinoid Agonists in Conscious Rats. <i>Journal of Neurogastroenterology and Motility</i> , 2019, 25, 300-315.	2.4	6
61	Nutraceuticals and peripheral glial cells: a possible link?. <i>Journal of Integrative Neuroscience</i> , 2022, 21, 001.	1.7	6
62	Cannabis and Cannabinoids and the Effects on Gastrointestinal Function: An Overview. , 2017, , 471-480.		5
63	Co-treatment With BGP-15 Exacerbates 5-Fluorouracil-Induced Gastrointestinal Dysfunction. <i>Frontiers in Neuroscience</i> , 2019, 13, 449.	2.8	5
64	Effects of the food additive monosodium glutamate on cisplatin-induced gastrointestinal dysmotility and peripheral neuropathy in the rat. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14020.	3.0	5
65	Effects of two different acute and subchronic stressors on gastrointestinal transit in the rat: A radiographic analysis. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14232.	3.0	5
66	Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions. <i>Biologics</i> , 2021, 1, 189-210.	4.1	5
67	Dependency on sex and stimulus quality of nociceptive behavior in a conscious visceral pain rat model. <i>Neuroscience Letters</i> , 2021, 746, 135667.	2.1	4
68	Changes in Fatty Acid Dietary Profile Affect the Brain-Gut Axis Functions of Healthy Young Adult Rats in a Sex-Dependent Manner. <i>Nutrients</i> , 2021, 13, 1864.	4.1	4
69	Lipidomics as Tools for Finding Biomarkers of Intestinal Pathology: From Irritable Bowel Syndrome to Colorectal Cancer. <i>Current Drug Targets</i> , 2022, 23, 636-655.	2.1	4
70	Cannabis, Cannabinoids, and Visceral Pain. , 2017, , 439-449.		3
71	Preclinical models of irritable bowel syndrome. , 2020, , 233-276.		3
72	Blockade of Gi/o proteins modifies electrical activity of S-myenteric neurons from guinea-pig ileum. <i>Neuroscience Letters</i> , 2004, 356, 175-178.	2.1	2

#	ARTICLE	IF	CITATIONS
73	213 THE CANNABINOID AGONIST WIN 55,212-2 PREVENTS THE DEVELOPMENT OF MECHANICAL ALLODYNIA INDUCED BY CHRONIC CISPLATIN IN THE RAT. European Journal of Pain, 2006, 10, S58b-S58.	2.8	2
74	Computer vision-based diameter maps to study fluoroscopic recordings of small intestinal motility from conscious experimental animals. Neurogastroenterology and Motility, 2017, 29, e13052.	3.0	2
75	Adherence to the Mediterranean diet: An online questionnaire based-study in a Spanish population sample just before the Covid-19 lockdown. Functional Foods in Health and Disease, 2021, 11, 283.	0.6	2
76	Effects of Commercial Probiotics on Colonic Sensitivity after Acute Mucosal Irritation. International Journal of Environmental Research and Public Health, 2022, 19, 6485.	2.6	1
77	282 THE CANNABINOID AGONIST WIN 55,212-2 BOTH REVERTS AND PREVENTS SIGNS OF PERIPHERAL NEUROPATHY INDUCED BY CHRONIC CISPLATIN IN THE RAT. European Journal of Pain, 2007, 11, S125-S125.	2.8	0
78	Young GI angle: Boosting your career development with fellowship experience. United European Gastroenterology Journal, 2018, 6, 331-332.	3.8	0
79	Caracterización fluoroscópica en rata de la dismotilidad colónica asociada a tratamiento con morfina. Revista De La Sociedad Espanola Del Dolor, 2017, , .	0.1	0
80	P.0886 Cannabinoids in the prevention of behavioral and brain deficits in a schizophrenia-like rat model. European Neuropsychopharmacology, 2021, 53, S649-S650.	0.7	0
81	P.0252 N-acetylcysteine supplement during pregnancy may prevent some of the behavioral and neuroanatomical deficits in a schizophrenia-like rat model. European Neuropsychopharmacology, 2021, 53, S183-S184.	0.7	0